Replies to post #105 on Equity Field Notes from temporal sources

[DanWebzster]

VTVT lead drug failed, as most expected, in a Ph3 Alzheimers study 4/18.

Next in the pipeline are two Ph2 candidates in Type 2 diabetes

had $11.8mn on 12/31/17. will have to raise cash during H-1/18, probably on unfavorable terms.

may be EOY tax loss candidate, at best. Put on list for EOY evaluation.